Background. A trial of empirical
acid-suppressive
therapy is the usual practice for most patients with symptoms of
gastritis in primary care. Aim. To assess the relative efficacy of
Troxipide and
Ranitidine in patients with endoscopic
gastritis over a four-week period. Methods. In all, 142 patients were randomized to
Troxipide (100 mg tid) or
Ranitidine (150 mg bid) for a period of four weeks. The severity of the signs of endoscopic
gastritis at baseline and week 4 using a four-point scale and the subjective symptom severity at baseline and week 2 & week 4 using a Visual analog scale (VAS) were documented. Results.
Troxipide was found to be superior to
Ranitidine for both, the complete resolution and improvement of endoscopic
gastritis. Higher proportion of patients showed complete healing of erosions (88.14%), oozing (96.77%), and
edema (93.88%) with
Troxipide as compared to
Ranitidine (P < .01). Patients receiving
Troxipide also showed a greater improvement in the VAS scores for
abdominal pain, bloating, and
heartburn (P < .01). Both the drugs were found to be well tolerated. Conclusion. In patients with endoscopic
gastritis,
Troxipide, with its superior rate of improvement, resolution of signs, and subjective clinical symptoms, can be considered as an alternative to the commonly used antisecretory agents.